|
gptkbp:instanceOf
|
gptkb:controlled_substance
gptkb:benzodiazepine
gptkb:sedative-hypnotic_drug
|
|
gptkbp:ATCCode
|
N05CA06
|
|
gptkbp:brand
|
gptkb:Seconal
gptkb:Seconal_Sodium
|
|
gptkbp:CASNumber
|
309-43-3
|
|
gptkbp:chemicalFormula
|
C12H17N2NaO3
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
gptkb:porphyria
severe respiratory insufficiency
hypersensitivity to barbiturates
|
|
gptkbp:discoveredBy
|
gptkb:Donalee_L._Tabern
gptkb:Ernest_H._Volwiler
|
|
gptkbp:discoveredIn
|
1928
|
|
gptkbp:eliminationHalfLife
|
15-40 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
crystalline powder
|
|
gptkbp:legalStatus
|
gptkb:Schedule_II_(US)
Prescription only
|
|
gptkbp:listedOn
|
World Health Organization Model List of Essential Medicines (historically)
|
|
gptkbp:marketedAs
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
272.27 g/mol
|
|
gptkbp:overdoseSymptoms
|
gptkb:death
coma
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
dizziness
drowsiness
respiratory depression
dependence
|
|
gptkbp:solubility
|
water-soluble
|
|
gptkbp:synonym
|
quinalbarbitone sodium
sodium secobarbital
|
|
gptkbp:UNII
|
H3G3K65W8M
|
|
gptkbp:usedFor
|
insomnia
seizure control
preoperative sedation
|
|
gptkbp:usedIn
|
physician-assisted suicide (in some jurisdictions)
|
|
gptkbp:bfsParent
|
gptkb:Secobarbital
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
secobarbital sodium
|